478183-60-7

Basic information

• Product Name: (S)-2-(tert-butoxycarbonylamino)-3-cyclobutylpropanoic acid
• Synonyms: (S)-2-(tert-butoxycarbonylamino)-3-cyclobutylpropanoic acid;Boc-(S)-2-aMino-3-cyclobutylpropanoic acid;Boc-(S)-3-Cyclobutylalanine;(Tert-Butoxy)Carbonyl (S)-3-Cyclobutylalanine;Boc-L-Cyclobutylalanine DIPA;N-Boc-S-Cyclobutylalanine
• CAS NO: 478183-60-7
• Molecular Formula: C₁₂H₂₁NO₄
• Molecular Weight: 243.3
• Mol File: 478183-60-7.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: (S)-2-(tert-butoxycarbonylamino)-3-cyclobutylpropanoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-2-(tert-butoxycarbonylamino)-3-cyclobutylpropanoic acid(478183-60-7)
• EPA Substance Registry System: (S)-2-(tert-butoxycarbonylamino)-3-cyclobutylpropanoic acid(478183-60-7)

Safety Data

• Hazardous Substances Data: 478183-60-7(Hazardous Substances Data)

Usage

General Description

(S)-2-(tert-butoxycarbonylamino)-3-cyclobutylpropanoic acid is a chemical compound with the molecular formula C13H23NO4. It is a derivative of the amino acid proline, with a tert-butoxycarbonyl (Boc) protecting group attached to the amino group. The compound also contains a cyclobutyl group and a carboxylic acid group. It is commonly used as a building block in organic synthesis, particularly in the production of pharmaceuticals and other biologically active molecules. (S)-2-(tert-butoxycarbonylamino)-3-cyclobutylpropanoic acid is generally stable and can be stored at room temperature, making it a valuable tool in the development and production of new chemical compounds.

Upstream product

• 4415-82-1 cyclobutanemethanol 
• 1201593-65-8 (S)-2-amino-3-cyclobutylpropanoic acid 
• 24424-99-5 di-tert-butyl dicarbonate 
• 63659-30-3 cyclobutylmethyl methanesulfonate 
• 16408-62-1 cyclobutylmethyl iodide 

Downstream Products

• 918662-56-3 [2-cyclobutyl-1S-(methoxymethylcarbamoyl)ethyl]-carbamic acid tert-butyl ester 

Relevant articles and documents

Required Immunoproteasome Subunit Inhibition Profile for Anti-Inflammatory Efficacy and Clinical Candidate KZR-616 ((2 S,3 R)- N-((S)-3-(Cyclopent-1-en-1-yl)-1-((R)-2-methyloxiran-2-yl)-1-oxopropan-2-yl)-3-hydroxy-3-(4-methoxyphenyl)-2-((S)-2-(2-morpholinoacetamido)propanamido)propenamide)

Selective immunoproteasome inhibition is a promising approach for treating autoimmune disorders, but optimal proteolytic active site subunit inhibition profiles remain unknown. We reveal here our design of peptide epoxyketone-based selective low molecular mass polypeptide-7 (LMP7) and multicatalytic endopeptidase complex subunit-1 (MECL-1) subunit inhibitors. Utilizing these and our previously disclosed low molecular mass polypeptide-2 (LMP2) inhibitor, we demonstrate a requirement of dual LMP7/LMP2 or LMP7/MECL-1 subunit inhibition profiles for potent cytokine expression inhibition and in vivo efficacy in an inflammatory disease model. These and additional findings toward optimized solubility led the design and selection of KZR-616 disclosed here and presently in clinical trials for treatment of rheumatic disease.